U.S. states and territories can now apply to the Centers for Disease Control and Prevention (CDC) for funds to fight Zika locally. More than $85 million in redirected funds identified by the Department of Health and Human Services is being made available to support efforts to protect Americans from Zika infection and associated adverse health outcomes, including the serious birth defect microcephaly.
"These funds will allow states and territories to continue implementation of their Zika preparedness plans, but are not enough to support a comprehensive Zika response and can only temporarily address what is needed,” said Stephen C. Redd, MD, (RADM, USPHS), director of CDC’s Office of Public Health Preparedness and Response. "Without the full amount of requested emergency supplemental funding, many activities that need to start now are being delayed or may have to be stopped within months.”
Under the latest announcement, $25 million in FY 2016 preparedness and response funding will go to 53 states, cities, and territories at risk for outbreaks of Zika virus infection. Recipients will receive funds based on the geographic locations of the two mosquitoes known to transmit Zika virus, Aedes aegypti and Aedes albopictus; history of mosquito borne disease outbreaks; and size of population. Jurisdictions will use the funds to strengthen incident management and emergency operations coordination; information management and sharing; and community recovery and resilience.
State, local and territorial health officials can use the funds to rapidly identify and investigate a possible outbreak of Zika virus disease in their communities; coordinate a comprehensive response across all levels of government and non-governmental partners (including the healthcare sector); and identify and connect to community services families affected by Zika virus disease.
Applications for the funds are due to CDC by June 13, 2016. Funds will be disbursed during the summer and remain available through July 2017.
Earlier this year, states and cities currently participating in the Epidemiology and Lab Capacity (ELC) program became eligible for more than $60 million to:
• build laboratory capacity,
• enhance epidemiological surveillance and investigation,
• improve mosquito control and monitoring,
• keep blood supplies safe, and
• contribute data to the U.S. Zika Pregnancy registry.
Applications for these funds are due May 27, 2016, and will be disbursed during the summer.
Zika virus disease is caused by Zika virus that is spread to people primarily through the bite of infected Aedes aegypti and Aedes albopictus mosquitoes, though Aedes aegypti are more likely to spread Zika. Sexual transmission also has been documented. There is currently no vaccine or treatment for Zika. The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis (red eyes). In previous outbreaks, the illness has typically been mild with symptoms lasting for several days to a week after being bitten by an infected mosquito. Zika virus infection in pregnant women is a cause of microcephaly and other severe fetal brain defects. Zika also has been linked to Guillain-Barré syndrome, an uncommon sickness of the nervous system in which a person’s immune system damages the nerve cells, causing muscle weakness and sometimes paralysis.
Source: CDC
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.